{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:07:34Z","timestamp":1790683654428,"version":"4.1.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1097\/cmr.0b013e32832bbde6","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T09:57:19Z","timestamp":1242899839000},"page":"185-192","source":"Crossref","is-referenced-by-count":29,"title":["Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma"],"prefix":"10.1097","volume":"19","author":[{"given":"Tim","family":"Eisen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson H.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Wolter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Kavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"L\u00f3pez Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Lardelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210129","article-title":"Cancer incidence, mortality and prevalance worldwide, Version 1.0. IARC Cancer Base No.5","year":"2001"},{"key":"R2-9-20210129","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11864-001-0033-5","article-title":"Metastatic melanoma","volume":"1","author":"Sun","year":"2001","journal-title":"Curr Treat Options Oncol"},{"key":"R3-9-20210129","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1517\/13543784.14.7.885","article-title":"Novel agents in development for the treatment of melanoma","volume":"14","author":"Tarhini","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"R4-9-20210129","first-page":"1234","article-title":"Interleukin-2 for the treatment of melanoma","volume":"6","author":"Tarhini","year":"2005","journal-title":"Curr Opin Investig Drugs"},{"key":"R5-9-20210129","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.critrevonc.2006.11.007","article-title":"Novel treatment strategies for malignant melanoma: a new beginning?","volume":"62","author":"Kasper","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"R6-9-20210129","first-page":"527","article-title":"Relevance and necessity of studies on second-line chemotherapy in melanoma","volume":"27","author":"Agarwala","year":"2004","journal-title":"Onkologie"},{"key":"R7-9-20210129","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1038\/sj.onc.1205972","article-title":"Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta","volume":"21","author":"Garcia-Fernandez","year":"2002","journal-title":"Oncogene"},{"key":"R8-9-20210129","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1038\/sj.onc.1207636","article-title":"JNK activation is critical for Aplidin-induced apoptosis","volume":"23","author":"Cuadrado","year":"2004","journal-title":"Oncogene"},{"key":"R9-9-20210129","first-page":"5580","article-title":"JNK activation as an in vivo marker of Aplidin [abstract]","volume":"2007","author":"Mu\u00f1oz","year":"2007","journal-title":"AACR Annual Meeting"},{"key":"R10-9-20210129","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1074\/jbc.M201010200","article-title":"Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK","volume":"278","author":"Cuadrado","year":"2003","journal-title":"J Biol Chem"},{"key":"R11-9-20210129","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1038\/sj.cdd.4401898","article-title":"Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation","volume":"13","author":"Gonzalez-Santiago","year":"2006","journal-title":"Cell Death Differ"},{"key":"R12-9-20210129","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/annonc\/mdi311","article-title":"VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia","volume":"16","author":"Biscardi","year":"2005","journal-title":"Ann Oncol"},{"key":"R13-9-20210129","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1038\/sj.bjc.6601864","article-title":"Antiangiogenic activity of aplidine, a new agent of marine origin","volume":"90","author":"Taraboletti","year":"2004","journal-title":"Br J Cancer"},{"key":"R14-9-20210129","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/sj.leu.2402788","article-title":"Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4","volume":"17","author":"Broggini","year":"2003","journal-title":"Leukemia"},{"key":"R15-9-20210129","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00280-005-0014-7","article-title":"Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes","volume":"57","author":"Straight","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"R16-9-20210129","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/bjc.1998.570","article-title":"In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells","volume":"78","author":"Depenbrock","year":"1998","journal-title":"Br J Cancer"},{"key":"R17-9-20210129","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1038\/sj.leu.2402972","article-title":"In vitro cytotoxicity of aplidin and crossresistance with other cytotoxic drugs in childhood leukemic and normal bone marrow and blood samples: a rational basis for clinical development","volume":"17","author":"Bresters","year":"2003","journal-title":"Leukemia"},{"key":"R18-9-20210129","first-page":"734","article-title":"Phase I and pharmacokinetic (PK) study of Aplidin (APL) using a 24-h, weekly schedule","volume":"19","author":"Anthoney","year":"2000","journal-title":"[Abstract] Proc Am Soc Clin Oncol"},{"key":"R19-9-20210129","first-page":"476","article-title":"Phase I clinical and pharmacokinetic (PK) study of the marine compound Aplidin (APL), administered as a 1\u2009h weekly infusion [abstract]","volume":"20","author":"Bowman","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R20-9-20210129","doi-asserted-by":"crossref","first-page":"7871","DOI":"10.1200\/JCO.2005.09.357","article-title":"Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies","volume":"23","author":"Faivre","year":"2005","journal-title":"J Clin Oncol"},{"key":"R21-9-20210129","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00001813-200404000-00003","article-title":"Progress in the clinical development of new marine-derived anticancer compounds","volume":"15","author":"Jimeno","year":"2004","journal-title":"Anticancer Drugs"},{"key":"R22-9-20210129","first-page":"422","article-title":"Phase I clinical and pharmacokinetic study of the marine compound Aplidin (APL) administered as a 3\u2009h infusion every 2 weeks [abstract]","volume":"21","author":"Ciruelos","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R23-9-20210129","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/annonc\/mdl165","article-title":"Phase I study of Aplidine in a daily\u00d75 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115","volume":"17","author":"Maroun","year":"2006","journal-title":"Ann Oncol"},{"key":"R24-9-20210129","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R25-9-20210129","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1200\/JCO.2000.18.20.3558","article-title":"Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines","volume":"18","author":"Ozer","year":"2000","journal-title":"J Clin Oncol"},{"key":"R26-9-20210129","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.1999.17.9.2971","article-title":"Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology","volume":"17","author":"Gralla","year":"1999","journal-title":"J Clin Oncol"},{"key":"R28-9-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"R29-9-20210129","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","article-title":"Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma","volume":"17","author":"Chapman","year":"1999","journal-title":"J Clin Oncol"},{"key":"R30-9-20210129","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1517\/14712598.7.3.345","article-title":"Immunotherapy of melanoma: a critical review of current concepts and future strategies","volume":"7","author":"Riker","year":"2007","journal-title":"Expert Opin Biol Ther"},{"key":"R31-9-20210129","first-page":"7505","article-title":"Randomized multinational phase 3 trial of decarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients with advanced malignant melanoma: analysis of long-term survival","volume":"22","author":"Millward","year":"2004","journal-title":"J Clin Oncol (ASCO Annual Meeting Proceedings)"},{"key":"R32-9-20210129","first-page":"A2068","article-title":"A phase III multicenter randomized trial of DTIC, cisplatin, BCNU and tamoxifen versus DTIC alone in patients with metastatic melanoma","volume":"18","author":"Saxman","year":"1999","journal-title":"J Clin Oncol"},{"key":"R33-9-20210129","first-page":"CD005413","article-title":"Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.","volume":"24","author":"Sasse","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"R34-9-20210129","first-page":"753","article-title":"Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy","volume":"2","author":"Lev","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"R35-9-20210129","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2004.11.070","article-title":"Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo","volume":"22","author":"Lev","year":"2004","journal-title":"J Clin Oncol"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00008390-200906000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:50:37Z","timestamp":1786038637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00008390-200906000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0b013e32832bbde6","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}